Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 1:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 927 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Vascular Disease Risk Clear all
Completed Not applicable Interventional

Simultaneous Risk Factor Control Using Telehealth to slOw Progression of Diabetic Kidney Disease (STOP-DKD)

NCT01829256
View directory record Official record
Conditions
Diabetes, Hypertension, Diabetic Kidney Disease
Interventions
Pharmacist telehealth intervention
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Oct 15, 2026, 1:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Inflammation and Cardiovascular Health in Women

NCT04224181
View directory record Official record
Conditions
HIV/AIDS, Myocardial Infarction
Interventions
Cardiac PET, 99mTc-tilmanocept SPECT/CT, Contrast Enhanced Coronary and Aortic Computed Tomography Angiography
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 79 Years · Female only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 15, 2026, 1:32 PM EDT
Recruiting No phase listed Observational

Risk Factors That Increase the Chance of Developing Primary Graft Dysfunction After Lung Transplantation

NCT00552357
View directory record Official record
Conditions
Primary Graft Dysfunction, Lung Transplantation
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
13 Years to 68 Years
Enrollment
1,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 15, 2026, 1:32 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Genetic Architecture of Natriuretic Peptides and Blood Pressure Response

NCT07118592
View directory record Official record
Conditions
Hypertension (HTN), Cardiometabolic Diseases
Interventions
Low Salt Diet, High Salt Diet, Saline Infusion
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 15, 2026, 1:32 PM EDT
Completed Phase 4 Interventional Results available

Clinical Effects of Eptifibatide Administration in High Risk Patients Presenting With Non-ST Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Urgent Coronary Artery Bypass Graft Surgery in Short- and Long-Term Follow-up

NCT01863134
View directory record Official record
Conditions
Non ST Elevation Myocardial Infarction
Interventions
Eptifibatide, Placebo
Drug
Lead sponsor
Medical University of Silesia
Other
Eligibility
21 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Oct 15, 2026, 1:32 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Health Electronic Assessment of Risks and Trends Using Biometric Equipment and Technology

NCT06753045
View directory record Official record
Conditions
Heart Diseases
Interventions
Smartwatch
Other
Lead sponsor
Tulane University
Other
Eligibility
18 Years to 120 Years
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
3
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 15, 2026, 1:32 PM EDT
Completed Phase 1Phase 2 Interventional

Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma

NCT00499577
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
CMV pp65 peptide, hTERT I540/R572Y/D988Y multipeptide vaccine, pneumococcal polyvalent vaccine, survivin Sur1M2 peptide vaccine
Biological
Lead sponsor
University of Maryland Greenebaum Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 10, 2014 · Synced Oct 15, 2026, 1:32 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Risk of Oxygen During Cardiac Surgery Trial

NCT02361944
View directory record Official record
Conditions
Cardiac Surgery
Interventions
Oxygen - normoxia, Oxygen - hyperoxia
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 15, 2026, 1:32 PM EDT
Completed Phase 2 Interventional

Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma

NCT00006219
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
clarithromycin, prasterone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 4, 2011 · Synced Oct 15, 2026, 1:32 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Cognitive Strategies for Optimizing Brain Health And Managing Transgenerational Vascular Risk Factors Post-Stroke

NCT06479174
View directory record Official record
Conditions
Stroke, Ischemic
Interventions
CHAMPS-TR
Behavioral
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 15, 2026, 1:32 PM EDT
Completed Not applicable Interventional

Improving Care for Patients With High Blood Pressure

NCT01425515
View directory record Official record
Conditions
Hypertension, Cardiovascular Disease Risk
Interventions
Complex quality improvement intervention
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Kinston, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Oct 15, 2026, 1:32 PM EDT
Recruiting Phase 2 Interventional

Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients

NCT05776979
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Isatuximab, lenalidomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 72 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 15, 2026, 1:32 PM EDT
Completed Not applicable Interventional Results available

Study of the Arachidonate 5-Lipoxygenase Enzyme in Affecting the Risk for Coronary Heart Disease

NCT00379808
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
montelukast, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 23, 2012 · Synced Oct 15, 2026, 1:32 PM EDT
Completed No phase listed Observational

Evaluation of the Effectiveness of Eliquis ® (Apixaban) Risk Minimization Tools in European Economic Area (EEA) Countries

NCT02339818
View directory record Official record
Conditions
Stroke, Systemic Embolism, VTEt and VTEp
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 15, 2026, 1:32 PM EDT
Completed Phase 4 Interventional

A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels

NCT00327691
View directory record Official record
Conditions
Cardiovascular Disease, Cerebrovascular Accident, Coronary Heart Disease
Interventions
Atorvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
35 Years to 75 Years
Enrollment
8,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
181
States / cities
Alabaster, Alabama • Birmingham, Alabama • Hoover, Alabama + 129 more
Source: ClinicalTrials.gov public record
Updated May 3, 2007 · Synced Oct 15, 2026, 1:32 PM EDT
Active, not recruiting Phase 2 Interventional

CAR- PRISM (PRecision Intervention Smoldering Myeloma)

NCT05767359
View directory record Official record
Conditions
Multiple Myeloma, Smoldering Multiple Myeloma
Interventions
Ciltacabtagene Autoleucel, Cyclophosphamide, Fludarabine Phosphate
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2040
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 15, 2026, 1:32 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event

NCT07000123
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
AZD0780, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
3,103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
101
States / cities
Huntsville, Alabama • Irondale, Alabama • Mobile, Alabama + 92 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 15, 2026, 1:32 PM EDT
Completed Phase 1Phase 2 Interventional

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

NCT02649790
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS), Acute Myeloid Leukemia (AML), Newly Diagnosed Intermediate/High-Risk MDS
Interventions
KPT-8602, ASTX727, Dexamethasone
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
26
States / cities
Los Angeles, California • Pasadena, California • Aurora, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 15, 2026, 1:32 PM EDT
Withdrawn Not applicable Interventional

Impact of GDT in Robot-assisted Laparoscopic Urological Surgery for Low to Moderate Risk Patients

NCT03213574
View directory record Official record
Conditions
Vascular Hypotension, Hypovolemia, Hypervolemia
Interventions
Control Group, Treatment Group
Other
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 15, 2026, 1:32 PM EDT
Recruiting Not applicable Interventional

Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke

NCT04897334
View directory record Official record
Conditions
Ischemic Stroke, Cognitive Impairment
Interventions
tDCS, sham tDCS, Cognitive Therapy
Device · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 90 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 15, 2026, 1:32 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The Path to Optimal Black Maternal Heart Health: Comparing Two CVD Risk Reduction Interventions (Change of HEART)

NCT05499507
View directory record Official record
Conditions
Pregnancy Related, Hypertension, Obesity, Racism
Interventions
COH+
Behavioral
Lead sponsor
Temple University
Other
Eligibility
18 Years and older · Female only
Enrollment
345 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 15, 2026, 1:32 PM EDT
Withdrawn Phase 3 Interventional

Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer

NCT04225299
View directory record Official record
Conditions
Localized Prostate Cancer
Interventions
TOOKAD®
Drug
Lead sponsor
Steba Biotech S.A.
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 15, 2026, 1:32 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Genetic Risk Stratification for Primary Prevention of CAD in Men and Pre & Post-menopausal Women

NCT05169840
View directory record Official record
Conditions
Coronary Artery Disease, Genetic Predisposition to Disease
Interventions
Genetic Risk Score for Coronary Artery Disease
Other
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
40 Years to 60 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
3
States / cities
Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Oct 15, 2026, 1:32 PM EDT
Terminated Phase 3 Interventional Results available

Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension

NCT00170950
View directory record Official record
Conditions
Hypertension
Interventions
Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1, Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2, Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter, Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1, Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2, Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter
Drug
Lead sponsor
Novartis
Industry
Eligibility
55 Years and older
Enrollment
11,506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Oct 15, 2026, 1:32 PM EDT